

MAY 23 2003

K030889

# 510(k) Summary

## As Required by 21 section 807.92 ( c )

- 1-Submitter Name: Mansour Consulting LLC  
2-Address: 1308 Morningside Park Dr  
Alpharetta, GA 30022 USA  
3-Phone: (678) 908- 8180  
4-Fax: (425) 795- 9341  
5-Contact Person: Jay Mansour  
6-Date summary prepared: March 18<sup>th</sup>, 2003  
7-Device Trade or Proprietary Name: ULTRA EKOGEL™  
8-Device Common or usual name: ULTRASOUND GEL  
9-Device Classification Name: SYSTEM, IMAGING, PULSED ECHO,  
ULTRASONIC- GEL  
10-Substantial Equivalency is claimed against the following device:  
• AQUASONIC 100 from Parker Laboratories, Inc.  
510k # K802146

### 11-Description of the Device:

ULTRA EKOGEL™ is an electroconductive gel media used with ultrasonic pulsed echo imaging system. The gel —once applied on the defined area of the body- facilitates the intended use of the system, which is intended to project a pulsed sound beam into body tissue to determine the depth or location of the tissue interfaces and to measure the duration of an acoustic pulse from the transmitter to the tissue interface and back to the receiver. It is supplied in 250 grams and 5 Kilograms containers with a 3-year shelf life.

### 12-Intended use of the device: (refer to FDA form attached)

ULTRA EKOGEL™ is an electroconductive gel media used with ultrasonic pulsed echo imaging system. The gel —once applied on the defined area of the body- facilitates the intended use of the system, which is intended to project a pulsed sound beam into body tissue to determine the depth or location of the tissue interfaces and to measure the duration of an acoustic pulse from the transmitter to the tissue interface and back to the receiver.

### 13-Safety and Effectiveness of the device:

This device is safe and effective as the other predicate device cited above.  
This is better expressed in the tabulated comparison (Paragraph 14 below)

### 14-Summary comparing technological characteristics with other predicate device:

Please find below a tabulated comparison supporting that this device is substantially equivalent to other medical devices in commercial distribution. Also, Equivalency overview chart path is attached. Indeed, this device is IDENTICAL to the predicate device. Refer to the explanations within the main submission.

FDA file reference number	510k # K802146
Attachments inside notification submission file	510k summary print out
<b>TECHNOLOGICAL CHARACTERISTICS</b>	<b>Comparison result</b>
Indications for use	Identical
Target population	Identical
Design	Identical
Materials	Identical
Performance	Identical
Sterility	Identical
Biocompatibility	Identical
Mechanical safety	Identical
Chemical safety	Identical
Anatomical sites	Identical
Human factors	Identical
Energy used and/or delivered	Identical
Compatibility with environment and other devices	Identical
Where used	Identical
Standards met	Identical
Electrical safety	Identical
Thermal safety	Identical
Radiation safety	Identical

7



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

**MAY 23 2003**

INMED, LTDA  
% Mr. Jay Mansour  
President  
Mansour Consulting, LLC  
1308 Morningside Park Dr.  
ALPHARETTA GA 30022

Re: K030889  
Trade/Device Name: ULTRA EKOGEL™  
Regulation Number: 21 CFR 892.1570  
Regulation Name: Diagnostic ultrasonic  
transducer  
Regulatory Class: II  
Product Code: 90 MUI  
Dated: March 18, 2003  
Received: March 21, 2003

Dear Mr. Mansour:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.


This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of the letter:

8xx.1xxx	(301) 594-4591
876.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,



Nancy C. Brogdon  
Director, Division of Reproductive,  
Abdominal and Radiological Devices  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

K030889

Page 1 of 1

510(k) Number (if known): K030889

Device Name: ULTRAEOGEL™

Indications for Use:

ULTRAEOGEL™ is an electroconductive gel media used with ultrasonic pulsed echo imaging system. The gel —once applied on the defined area of the body- facilitates the intended use of the system, which is intended to project a pulsed sound beam into body tissue to determine the depth or location of the tissue interfaces and to measure the duration of an acoustic pulse from the transmitter to the tissue interface and back to the receiver.

*David R. Lyons*

(Division Sign-Off)  
Division of Reproductive, Abdominal,  
and Radiological Devices  
510(k) Number K030889

*Prescription Use* ✓

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE  
OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Optional Format 3-10-98)

10